Discrepancy between PSA Levels and Gleason Score in Prostate Cancer from Northern Nigeria: A Histopathological Analysis
DOI:
https://doi.org/10.56919/usci.2542.032Keywords:
Prostatic lesions, Prostate-Specific Antigens, Gleason scoreAbstract
An extensively utilized tumor marker for prostate cancer is prostate-specific antigen (PSA). It's well known that PSA is a marker specific to the prostate rather than a disease. The study aims to determine the relationship between prostate-specific antigen and various prostatic lesions in some states in North-western Nigeria. This study included 224 samples from the histopathology laboratory of two teaching hospitals in North-western Nigeria. Representative tissue was obtained from the samples, and paraffin-embedded tissue blocks were made, sectioned, and stained with hematoxylin and eosin. The slides underwent light microscopy examination for a final assessment and diagnosis. An Electrochemiluminescence immunoassay was used to measure serum PSA levels. The study analyzed 224 samples, revealing benign prostatic hyperplasia in 54.9% of cases, while prostate adenocarcinoma was the most common malignancy, accounting for 35.7% of cases. Normal PSA levels were found in 17.0% of BPH cases and 11.2% of prostate cancer cases. Benign lesions (54.9% BPH) showed elevated PSA (>20 ng/ml) in 27.7% of cases, while 58.8% of malignancies had PSA >20 ng/ml. The findings show a statistically significant correlation (p <0.05) between prostatic lesions and serum total PSA levels, and no significant association between PSA levels and Gleason scores (r = 0.098, p>0.05). Serum PSA levels can rise due to both benign and malignant tumors, and the likelihood that a benign disease would progress to a malignant one increases with increased PSA levels. Adults over 40 must consider preventative steps like prostate cancer screening.
References
Abubakar, A., Alhaji, S. A., Sanusi, H. M., Aliyu, S., Musa, M. U., & Abdullahi, A. S. (2019). Histopathological pattern of prostatic lesions in Kano, North-western Nigeria: A 14-year review. Annals of Tropical Pathology, 10(2), 150–154. https://journals.lww.com/antp/fulltext/2019/10020/histopathological_pattern_of_prostatic_lesions_in.10.aspx
Abubakar, M., Shehu, S. M., Ahmed, A. A., Liman, A. A., Akpobi, K. C., Mohammed, A., et al. (2018). Adenocarcinoma of the prostate: Correlation between serum prostate-specific antigen and Gleason grade group. Annals of Tropical Pathology, 9, 126–130. https://doi.org/10.4103/atp.atp_28_18 DOI: https://doi.org/10.4103/atp.atp_28_18
Albasri, A., El-Siddig, A., Hussainy, A., Mahrous, M., Alhosaini, A. A., & Alhujaily, A. (2014). Histopathologic characterization of prostate diseases in Madinah, Saudi Arabia. Asian Pacific Journal of Cancer Prevention, 15(10), 4175–4179. https://doi.org/10.7314/APJCP.2014.15.10.4175 DOI: https://doi.org/10.7314/APJCP.2014.15.10.4175
American Cancer Society. (2015). Prostate cancer. http://www.cancer.org/cancer/prostate-cancer/detailed-guide/index
Anderson-Jackson, L., McGrowder, D. A., & Alexander-Lindo, R. (2012). Prostate-specific antigen and Gleason score in men with prostate cancer at a private diagnostic radiology centre in Western Jamaica. Asian Pacific Journal of Cancer Prevention, 13(4), 1453–1456. https://doi.org/10.7314/APJCP.2012.13.4.1453 DOI: https://doi.org/10.7314/APJCP.2012.13.4.1453
Anunobi, C. C., Akinde, O. R., Elesha, S. O., Daramola, A. O., Tijani, K. H., & Ojewola, R. W. (2011). Prostate diseases in Lagos, Nigeria: A histologic study with tPSA correlation. The Nigerian Postgraduate Medical Journal, 18(2), 98–104. https://doi.org/10.4103/1117-1936.170330 DOI: https://doi.org/10.4103/1117-1936.170330
Banerjee, B., Iqbal, B. M., Kumar, H., Kambale, T., & Bavikar, R. (2016). Correlation between prostate-specific antigen levels and various prostatic pathologies. Journal of Medical Society, 30(3), 172–175. https://doi.org/10.4103/0972-4958.191184 DOI: https://doi.org/10.4103/0972-4958.191184
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492 DOI: https://doi.org/10.3322/caac.21492
Crawford, E. D. (2003). Epidemiology of prostate cancer. Urology, 62(6), 3–12. https://doi.org/10.1016/j.urology.2003.10.013 DOI: https://doi.org/10.1016/j.urology.2003.10.013
Dalton, D. L. (1989). Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology, 33(6), 465. https://doi.org/10.1016/0090-4295(89)90131-3 DOI: https://doi.org/10.1016/0090-4295(89)90131-3
Farmer, R. (2008). Prostate cancer: Epidemiology and risk factors. Trends in Urology, Gynaecology & Sexual Health, 13(3), 32–34. https://doi.org/10.1002/tre.71 DOI: https://doi.org/10.1002/tre.71
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021). Cancer statistics for the year 2020: An overview. International Journal of Cancer. Advance online publication. https://doi.org/10.1002/ijc.33588 DOI: https://doi.org/10.1002/ijc.33588
Filella, X., & Foj, L. (2016). Prostate cancer detection and prognosis: From prostate-specific antigen (PSA) to exosomal biomarkers. International Journal of Molecular Sciences, 17(11), 1784. https://doi.org/10.3390/ijms17111784 DOI: https://doi.org/10.3390/ijms17111784
Gill, N., Zouwail, S., & Joshi, H. (2018). Prostate-specific antigen: A review of assay techniques, variability and their clinical implications. BioNanoScience, 8, 707–712. https://doi.org/10.1007/s12668-017-0465-4 DOI: https://doi.org/10.1007/s12668-017-0465-4
Graham, J., Baker, M., Macbeth, F., Titshall, V., & Guideline Development Group. (2008). Diagnosis and treatment of prostate cancer: Summary of NICE guidance. BMJ, 336(7644), 610–612. https://doi.org/10.1136/bmj.39498.525706.AD DOI: https://doi.org/10.1136/bmj.39498.525706.AD
Gurumurthy, D., Maggad, R., & Patel, S. (2015). Prostate carcinoma: Correlation of histopathology with serum prostate-specific antigen. Science Journal of Clinical Medicine, 4(4), 1–5. https://doi.org/10.11648/j.sjcm.s.2015040401.11 DOI: https://doi.org/10.11648/j.sjcm.s.2015040401.11
Hirachand, S., Dangol, U. M. S., Pradhanang, S., & Acharya, S. (2017). Study of prostatic pathology and its correlation with prostate-specific antigen level. Journal of Pathology of Nepal, 7(1), 1074–1077. https://doi.org/10.3126/jpn.v7i1.16911 DOI: https://doi.org/10.3126/jpn.v7i1.16911
Huang, J., Chan, E. O., Liu, X., Lok, V., Ngai, C. H., Zhang, L., Xu, W., Zheng, Z. J., Chiu, P. K., Vasdev, N., Enikeev, D., Shariat, S. F., Ng, C. F., Teoh, J. Y., & Wong, M. C. S. (2023). Global trends of prostate cancer by age, and their associations with gross domestic product (GDP), human development index (HDI), smoking, and alcohol drinking. Clinical Genitourinary Cancer, 21(4), e261–e270.e50. https://doi.org/10.1016/j.clgc.2023.02.003 DOI: https://doi.org/10.1016/j.clgc.2023.02.003
Humphrey, P. A. (2017). Histopathology of prostate cancer. Cold Spring Harbor Perspectives in Medicine, 7(10), a030411. https://doi.org/10.1101/cshperspect.a030411 DOI: https://doi.org/10.1101/cshperspect.a030411
Iheanacho, C. O., & Enechukwu, O. H. (2025). Epidemiology of prostate cancer in Nigeria: A mixed-methods systematic review. Cancer Causes & Control, 36, 1–12. https://doi.org/10.1007/s10552-024-01917-w DOI: https://doi.org/10.1007/s10552-024-01917-w
Klein, J., & Von dem Knesebeck, O. (2015). Socioeconomic inequalities in prostate cancer survival: A review of the evidence and explanatory factors. Social Science & Medicine, 142, 9–18. https://doi.org/10.1016/j.socscimed.2015.07.006 DOI: https://doi.org/10.1016/j.socscimed.2015.07.006
Kraus, T. S., Cohen, C., & Siddiqui, M. T. (2010). Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma. Diagnostic Pathology, 5, 63. https://doi.org/10.1186/1746-1596-5-63 DOI: https://doi.org/10.1186/1746-1596-5-63
Lakhey, M., Ghimire, R., Shrestha, R., & Bhatta, A. D. (2010). Correlation of serum free prostate-specific antigen level with histological findings in patients with prostatic disease. Kathmandu University Medical Journal, 8(30), 158–163. https://doi.org/10.3126/kumj.v8i2.3550 DOI: https://doi.org/10.3126/kumj.v8i2.3550
Lilleby, W., Torlakovic, G., Torlakovic, E., Skovlund, E., & Fosså, S. D. (2001). Prognostic significance of histologic grading in patients with prostate carcinoma who are assessed by the Gleason and World Health Organization grading systems in needle biopsies obtained prior to radiotherapy. Cancer, 92(2), 311–319. [Crossref] DOI: https://doi.org/10.1002/1097-0142(20010715)92:2<311::AID-CNCR1324>3.0.CO;2-H
Maru, A. M., Makwana, H. H., Lakum, N. R., Chokshi, T., Agnihotri, A., Trivedi, N., & Joshi, J. (2014). Study on correlation between prostate-specific antigen (PSA) and various prostatic pathology. International Journal of Medical Science and Public Health, 3(6), 735–738. https://doi.org/10.5455/ijmsph.2014.040420142 DOI: https://doi.org/10.5455/ijmsph.2014.040420142
Mohammed, A. Z., Alhassan, S. U., Edino, S. T., & Ochicha, O. (2003). Histopathological review of prostatic diseases in Kano, Nigeria. The Nigerian Postgraduate Medical Journal, 10(1), 1–5. https://doi.org/10.4103/1117-1936.171600 DOI: https://doi.org/10.4103/1117-1936.171600
Montironi, R., Cheng, L., Scarpelli, M., & Lopez-Beltran, A. (2016). Pathology and genetics: Tumours of the urinary system and male genital system: Clinical implications of the 4th Edition of the WHO Classification and Beyond. European Urology, 70(1), 120–123. https://doi.org/10.1016/j.eururo.2016.03.011 DOI: https://doi.org/10.1016/j.eururo.2016.03.011
Mosli, H. A., Abdel-Meguid, T. A., Al-Maghrabi, J. A., Kamal, W. K., Saadah, H. A., & Farsi, H. M. (2009). The clinicopathologic patterns of prostatic diseases and prostate cancer in Saudi patients. Saudi Medical Journal, 30(11), 1439–1443.
Naing, L., Winn, T. B. N. R., & Rusli, B. N. (2006). Practical issues in calculating the sample size for prevalence studies. Archives of Orofacial Sciences, 1, 9–14.
Neal, D. E., Jr, Clejan, S., Sarma, D., & Moon, T. D. (1992). Prostate-specific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate. The Prostate, 20(2), 105–111. https://doi.org/10.1002/pros.2990200205 DOI: https://doi.org/10.1002/pros.2990200205
Nwafor, C. C., Keshinro, O. S., & Abudu, E. K. (2015). A histopathological study of prostate lesions in Lagos, Nigeria: A private practice experience. Nigerian Medical Journal, 56(5), 338–343. https://doi.org/10.4103/0300-1652.170388 DOI: https://doi.org/10.4103/0300-1652.170388
Obiorah, C. C., & Nwosu, S. O. (2011). A histopathological study of carcinoma of the prostate in Port Harcourt, Nigeria. Nigerian Journal of Clinical Practice, 14(3), 363–367. https://doi.org/10.4103/1119-3077.86785 DOI: https://doi.org/10.4103/1119-3077.86785
Pudasaini, S., Subedi, N., & Shrestha, N. M. (2019). Evaluation of prostate-specific antigen levels and its correlation with histopathological findings. Journal of Pathology of Nepal, 9(1), 1485–1489. https://doi.org/10.3126/jpn.v9i1.23376 DOI: https://doi.org/10.3126/jpn.v9i1.23376
Raphael, J. E., & Abhulimen, V. (2022). Age and Gleason's score in prostate cancer among Southern Nigerians: Is there any correlation? Journal of Cancer and Tumor International, 12(2), 8–15. https://doi.org/10.9734/jcti/2022/v12i230171 DOI: https://doi.org/10.9734/jcti/2022/v12i230171
Rawla, P. (2019). Epidemiology of prostate cancer. World Journal of Oncology, 10(2), 63–89. https://doi.org/10.14740/wjon1191 DOI: https://doi.org/10.14740/wjon1191
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021). Prostate cancer. Nature Reviews Disease Primers, 7(1), 9. https://doi.org/10.1038/s41572-020-00243-0 DOI: https://doi.org/10.1038/s41572-020-00243-0
Schröder, F. H., Wildhagen, M. F., & Rotterdam Study Group of the 'European Randomised Study of Screening for Prostate Cancer' (ERSPC). (2001). Screening for prostate cancer: Evidence and perspectives. BJU International, 88(8), 811–817. https://doi.org/10.1046/j.1464-4096.2001.02449.x DOI: https://doi.org/10.1046/j.1464-4096.2001.02449.x
Stimac, G., Spajic, B., Reljic, A., Katusic, J., Popovic, A., Grubisic, I., & Tomas, D. (2014). Effect of histological inflammation on total and free serum prostate-specific antigen values in patients without clinically detectable prostate cancer. Korean Journal of Urology, 55(8), 527–532. https://doi.org/10.4111/kju.2014.55.8.527 DOI: https://doi.org/10.4111/kju.2014.55.8.527
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660 DOI: https://doi.org/10.3322/caac.21660
Sweat, S. D., Bergstralh, E. J., Slezak, J., Blute, M. L., & Zincke, H. (2002). Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. The Journal of Urology, 168(2), 525–529. https://doi.org/10.1016/S0022-5347(05)64672-1 DOI: https://doi.org/10.1016/S0022-5347(05)64672-1
Udoh, E. A., David, D. E., & Eyo, A. E. (2020). Relationship between serum prostate-specific antigen (PSA) and Gleason score in patients diagnosed with prostate cancer: A hospital-based study. EAS Journal of Medicine and Surgery, 2(2), 47–52. https://doi.org/10.36349/EASJMS.2020.v02i02.011 DOI: https://doi.org/10.21276/ijcmr.2020.7.5.19
Umezurike, B. I., Ekanem, T. B., Eluwa, M. A., Etta, K. K., Udo-Affah, G. A., & Aligwekwe, A. U. (2006). The frequency of benign prostate hypertrophy in Calabar. The Nigerian Postgraduate Medical Journal, 13(3), 236–239. https://doi.org/10.4103/1117-1936.180580 DOI: https://doi.org/10.4103/1117-1936.180580
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
UMYU Scientifica recognizes the importance of protecting authors’ intellectual property while promoting the free exchange of scientific knowledge. The journal adopts a copyright-retention model that empowers authors to maintain ownership of their work while granting the journal rights necessary for publication and dissemination.
1. Copyright Ownership
Authors publishing with UMYU Scientifica retain full copyright and publishing rights to their work. By submitting a manuscript, authors agree to grant the journal a non-exclusive license to publish, reproduce, distribute, and archive the article in all forms and media for the purpose of scholarly communication.
2. Licensing Terms
All articles are published under the Creative Commons Attribution–NonCommercial (CC BY-NC) license.
This license permits others to:
- Share - copy and redistribute the material in any medium or format.
- Adapt - remix, transform, and build upon the material.
- For non-commercial purposes only, provided that proper credit is given to the original author(s) and UMYU Scientifica as the source, a link to the license is provided, and any modifications are clearly indicated.
Commercial reuse or distribution of the content requires written permission from both the author and the editorial office.
3. Author Rights
Authors are free to:
- Deposit all versions of their manuscript (preprint, accepted version, and published version) in institutional, disciplinary, or public repositories without embargo.
- Use and distribute their published article for non-commercial scholarly purposes, including teaching, conference presentations, and research sharing.
- Include their work in future books, theses, or compilations, provided proper citation to the journal is made.
4. Publisher’s Rights
Upon publication, UMYU Scientifica retains the right to:
- Host, index, and disseminate the article through the journal’s website and partner databases.
- Archive the content in long-term preservation systems such as the PKP Preservation Network (PKP-PN) and the Umaru Musa Yar’adua University Institutional Repository.
5. Attribution and Citation
Users must give appropriate credit to the author(s), include a link to the article’s DOI or the journal webpage, and indicate if changes were made. Proper citation is required whenever the work is reused or referenced.
6. License Reference
For detailed terms of use, please refer to the Creative Commons Attribution–NonCommercial 4.0 International License (CC BY-NC 4.0):
https://creativecommons.org/licenses/by-nc/4.0/
